ArticleIranian journal of pharmaceutical research : IJPR
Efficacy of a Saffron-Based (
Article in Iranian journal of pharmaceutical research : IJPR. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Sleep disturbances in pulmonary sarcoidosis increase fatigue and reduce quality of life; however, standard anti-inflammatory treatments provide limited benefit. Saffron ( Objectives: This study evaluated whether 60 days of saffron supplementation (30 mg twice daily) improves sleep quality, reduces daytime sleepiness and fatigue, and enhances quality of life in patients with pulmonary sarcoidosis. Methods: In this single-blind randomized controlled trial, 76 adults with pulmonary sarcoidosis, confirmed according to the American Thoracic Society/European Respiratory Society/World Association of Sarcoidosis and Other Granulomatous Disorders criteria, and Pittsburgh Sleep Quality Index (PSQI) scores ≥ 5 were assigned to groups using permuted block randomization (block size, 4). Allocation concealment was ensured using opaque, sealed, sequentially numbered envelopes. Participants were randomly allocated to receive either saffron (30 mg twice daily) plus sleep-hygiene counseling or counseling alone for 60 days. Sleep quality, daytime sleepiness, fatigue, and quality of life were assessed at baseline and day 60 using the PSQI, General Sleep Disturbance Scale (GSDS), Epworth Sleepiness Scale (ESS), Fatigue Assessment Scale (FAS), Patient-Reported Outcomes Measurement Information System (PROMIS)-fatigue, and 12-item Short Form Health Survey (SF-12). Results: Of the 76 participants enrolled, 72 completed the study (36 per group). Compared with the control group, saffron supplementation significantly improved PSQI (adjusted mean difference [MD], -2.21), GSDS (adjusted MD, -14.60), ESS (adjusted MD, -2.46), FAS (adjusted MD, -4.58), and the PROMIS global physical health score (adjusted MD, 1.65) (all P < 0.001). Significant improvements were also observed in the SF-12 physical (P = 0.03) and mental (P = 0.003) component scores. No serious adverse events occurred. Conclusions: Adjunctive saffron supplementation significantly improved sleep quality, reduced daytime sleepiness and fatigue, and enhanced quality of life in patients with pulmonary sarcoidosis. Larger, placebo-controlled studies are warranted to confirm these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.